ClinicalTrials.gg
CompletedNCT03251040SEALUpdated Aug 22, 2017

Fibrin Sealant in Esophageal Surgery

An interventional study of Autologous activated fibrin sealant in Anastomotic Leak, sponsored by Amsterdam UMC, location VUmc. Completed. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2017-08-22.

Sponsored by Amsterdam UMC, location VUmc · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 2 years after the study started (first participant enrolled Aug 2015, registered Aug 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Anastomotic leakage remains a major complication after esophageal surgery. Amongst other preventive measures, fibrin sealant is a promising adjunct to conventional anastomotic techniques. The investigators aimed to investigate feasibility of additional sealing by means of autologous fibrin sealant of the esophageal anastomosis.

02

Conditions studied

  • Anastomotic Leak

Browse trials for

Keywords

  • Esophagogastric anastomosis
  • Fibrin sealant
  • Sealing
03

In context

Anastomotic Leak

240 studies on the registry are indexed under Anastomotic Leak; 72 are open to participants now.

This study's enrollment of 15 is below the median of 140 across 128 interventional studies indexed under Anastomotic Leak.

Browse Anastomotic Leak studies →

Lead sponsor

Amsterdam UMC, location VUmc is the lead sponsor of 305 studies on the registry; 84 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 - 90 years
  • Scheduled to undergo elective minimal invasive esophageal surgery with thoracic or cervical anastomosis (i.e. Ivor Lewis, Orringer or McKeown esophagectomy).
  • physical status () of 3 or lower

Exclusion criteria

Exclusion Criteria:

  • Other
  • Previous esophageal surgery were excluded
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (actual)

Study arms

  • Other
    Fibrin sealant

    Single arm pilot study

    Device: Autologous activated fibrin sealant

Interventions

  • DeviceAutologous activated fibrin sealant

    Application of fibrin sealant

06

What researchers measure

Primary outcomes

  1. Anastomotic leakage

    Time frame: 30-day morbidity

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Plat VD, Bootsma BT, van der Wielen N, van der Peet DL, Daams F. Autologous Activated Fibrin Sealant for the Esophageal Anastomosis: A Feasibility Study. J Surg Res. 2019 Feb;234:49-53. doi: 10.1016/j.jss.2018.08.049. Epub 2018 Sep 27. PubMed 30527497 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2015 to primary completion in Apr 2016, 8 months.

Of 58 non-industry interventional studies with no phase under Anastomotic Leak, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 42. This study's 8 months is below that.

Counting every sponsor, half of 65 studies reached it within 32 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2017
First posted
Aug 16, 2017
StartActual
Aug 1, 2015
Primary completionActual
Apr 1, 2016
CompletionActual
May 1, 2017
Last update
Aug 22, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03251040
Responsible party
Victor Plat (Principal investigator, Amsterdam UMC, location VUmc) — Principal investigator
First posted
Aug 16, 2017
Start date
Aug 1, 2015
Primary completion
Apr 1, 2016
Completion
May 1, 2017
Last update
Aug 22, 2017

Study contacts

Freek Daams, MD PhD
study director · Amsterdam UMC, location VUmc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion